2022, Number 2
PDF size: 575.99 Kb.
ABSTRACTBackground: SARS-CoV-2 infection, which causes COVID-19, has impacted the entire world due to its extensive and rapid spread. In the last two years, more than 412 million cases have been confirmed, with more than 5.8 million deaths, as of February 14, 2022.
Objective: Integrate a series of recommendations based on the best level of evidence in prevention, diagnosis and treatment of SARS-CoV-2 infection, including its new variants.
Methodology: Review of different international guidelines and recent articles published in peer-reviewed journals. Issue recommendations based on the level of evidence and degree of confirmation established by the guidelines of the National Institute for Health and Care Excellence (NICE). The authors analyzed the selected articles and, based on their experience, summarized the most relevant to meet the objectives of these recommendations.
Results: 200 articles were found, of which only 124 were selected that met the requirements to identify the level of evidence and degree of recommendation.
Conclusions: Prevention through vaccination continues to be the best tool to establish protection mechanisms against the virus and substantially reduce hospitalizations and associated mortality. Although homologous vaccination is still the accepted reference pattern, the efficacy of heterologous schemes to avoid hospitalization and mortality must be considered. Monoclonal experiments, such as sotrovimab, have activity against the Ómicron variant and the AZD7442 molecule that have shown high efficacy in preventing symptomatic COVID-19 in pre- and post-exposure conditions.
Lyngse FP, Kirkeby CT, Denwood M, et al. Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households. medRxiv . 2022 Jan 30 [cited 2022 Feb 13];2022.01.28.22270044. Available from: https://www.medrxiv.org/content/ 10.1101/2022.01.28.22270044v1 doi: https://doi. org/10.1101/2022.01.28.22270044
Martinez-Baz I, Trobajo-Sanmartin C, Miqueleiz A, et al. Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. Euro Surveill. 2021 Sep;26(39):2100894. doi: 10.2807/1560-7917.ES.2021.26.39.2100894. PMID: 34596016; PMCID: PMC8485582..
Liu X, Shaw RH, Stuart ASV, Greenland M, et al. Safety and immunogenicity of heterologous versus homologous primeboost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021 Sep 4;398(10303):856- 869. doi: 10.1016/S0140-6736(21)01694-9. Epub 2021 Aug 6. PMID: 34370971; PMCID: PMC8346248..
Munro APS, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COVBOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021 Dec 18;398(10318):2258-2276. doi: 10.1016/S0140-6736(21)02717-3. Epub 2021 Dec 2. Erratum in: Lancet. 2021 Dec 18;398(10318):2246. PMID: 34863358; PMCID: PMC8639161.
Fares Qeadan, Nana A. Mensah, Benjamin Tingey, et al. Stanford. The risk of clinical complications and death among pregnant women with COVID-19 in the Cerner COVID-19 cohort: a retrospective análisis BMC Pregnancy Childbirth. 2021 Apr 16;21(1):305. doi: 10.1186/s12884- 021-03772-y. PMID: 33863292; PMCID: PMC8051832.
Lokken EM, Huebner EM, Taylor GG, et al. COVID-19 in Pregnancy Collaborative. Disease severity, pregnancy outcomes, and maternal deaths among pregnant patients with severe acute respiratory syndrome coronavirus 2 infection in Washington State. Am J Obstet Gynecol. 2021 Jul;225(1):77.e1-77.e14. doi: 10.1016/j.ajog.2020.12.1221. Epub 2021 Jan 27. PMID: 33515516; PMCID: PMC7838012.
Martinez-Portilla RJ, Sotiriadis A, Chatzakis C. Pregnant women with SARS-COV-2 infection are at higher risk of death and pneumonia: propensity score matched abalysis of a nationwide prospective cohort (COV19Mx). Ultrasound Obstet Gynecol. 2021 Feb;57(2):224-231. doi: 10.1002/ uog.23575. PMID: 33320401
Martinez-Portilla RJ, Smith ER, He S, et al. Young pregnant women are also at an increased risk of mortality and severe illness due to coronavirus disease 2019: analysis of the Mexican National Surveillance Program. Am J Obstet Gynecol. 2021 Apr;224(4):404-407. doi: 10.1016/j.ajog.2020.12.1197. Epub 2020 Dec 17. PMID: 33345802; PMCID: PMC7837025.
Dinnes J, Deeks J, Berhane S, et al. Cochrane COVID-19 Diagnostic Test Accuracy Group. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARSCoV- 2 infection. Cochrane Database Syst Rev. 2021 Mar 24;3(3):CD013705. doi: 10.1002/14651858.CD013705. pub2. PMID: 33760236; PMCID: PMC807859.
Pillaiyar T, Manickam M, Namasivayam V, et al. An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy. J Med Chem. 2016 Jul 28;59(14):6595-628. doi: 10.1021/acs.jmedchem.5b01461. Epub 2016 Feb 29. PMID: 26878082; PMCID: PMC7075650.
Su W, Sia SF, Schmitz AJ, et al. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters. mBio. 2021 Oct 26;12(5):e0239521. doi: 10.1128/mBio.02395-21. Epub 2021 Sep 14. PMID: 34517754; PMCID: PMC8546861.
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect Dis. 2021 Dec 23:S1473-3099(21)00751-9. doi: 10.1016/S1473- 3099(21)00751-9. Epub ahead of print. PMID: 34953520; PMCID: PMC8700279.